Home / Specialty Pharmacy (page 5)

Specialty Pharmacy

Horizon Pharma and HemoShear Therapeutics Enter Exclusive Drug Discovery Collaboration in Gout

DUBLIN & CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout. “As we continue to grow our pipeline, we are committed to addressing unmet treatment needs for people with gout as …

Read More »

Better Mouse Model Built to Enable Precision-Medicine Research for Alzheimer’s

Incorporating genetic diversity into a mouse model of Alzheimer’s disease resulted in greater overlap with the genetic, molecular and clinical features of this pervasive human disease, according to a study funded by the National Institute on Aging (NIA), part of the National Institutes of Health. The study also suggests that …

Read More »

FDA Approves Acorda’s Inbrija for Intermittent Treatment of OFF Episodes in Patients with Parkinson’s Disease

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low …

Read More »

Cigna Completes Combination with Express Scripts, Establishing a Blueprint to Transform the Health Care System

BLOOMFIELD, Conn.–(BUSINESS WIRE)–Cigna Corporation (NYSE: CI), a leading global health service company, has successfully completed its combination with Express Scripts Holding Company (“Express Scripts”) effective December 20, 2018. Consistent with its commitment to support local communities and improve societal health, Cigna also announced an incremental investment of $200 million to …

Read More »

Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Investigational Agent SEP-363856 for the Treatment of Schizophrenia

MARLBOROUGH, Mass. & PARAMUS, N.J.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc.(PsychoGenics), today announced that positive results from SEP 361-201, a pivotal Phase 2 study that evaluated the efficacy and safety of SEP-363856, a novel psychotropic agent for the treatment of patients with schizophrenia, were presented at the 57th Annual Meeting of the …

Read More »

Neurocrine’s Valbenazine Did Not Meet Primary Endpoint in Phase IIb Study in Pediatric Patients with Tourette Syndrome

SAN DIEGO, Dec. 12, 2018 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale (YGTSS) in children and adolescents with moderate to severe …

Read More »

Lilly and AC Immune Announce License and Collaboration Agreement for Potential Alzheimer’s Disease Therapies

INDIANAPOLIS and LAUSANNE, Switzerland, Dec. 12, 2018 /PRNewswire/ — Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development …

Read More »

Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions

THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company’s capabilities and resources to identify clinical gaps for some of the healthcare system’s most difficult-to-treat diseases. …

Read More »

Insys Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) — Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy, according to new clinical …

Read More »

Lundbeck and Otsuka Announce Positive Phase 2 Data for Combination Treatment of Brexpiprazole and Sertraline in Post-Traumatic Stress Disorder

Valby, Denmark and Tokyo, Japan, 30 November 2018 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today the achievement of positive clinical results (in intention-to-treat population) as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score change from baseline compared to placebo, when brexpiprazole and …

Read More »